CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen

Shiteng Duan, Cynthia J. Koziol-White, William F. Jester, Corwin M. Nycholat, Matthew S. Macauley, Reynold A. Panettieri, James C. Paulson

Research output: Contribution to journalArticle

15 Scopus citations


Allergen immunotherapy for patients with allergies begins with weekly escalating doses of allergen under medical supervision to monitor and treat IgE mast cell–mediated anaphylaxis. There is currently no treatment to safely desensitize mast cells to enable robust allergen immunotherapy with therapeutic levels of allergen. Here, we demonstrated that liposomal nanoparticles bearing an allergen and a high-affinity glycan ligand of the inhibitory receptor CD33 profoundly suppressed IgE-mediated activation of mast cells, prevented anaphylaxis in Tg mice with mast cells expressing human CD33, and desensitized mice to subsequent allergen challenge for several days. We showed that high levels of CD33 were consistently expressed on human skin mast cells and that the antigenic liposomes with CD33 ligand prevented IgE-mediated bronchoconstriction in slices of human lung. The results demonstrated the potential of exploiting CD33 to desensitize mast cells to provide a therapeutic window for administering allergen immunotherapy without triggering anaphylaxis.

Original languageEnglish (US)
Pages (from-to)1387-1401
Number of pages15
JournalJournal of Clinical Investigation
Issue number3
StatePublished - Mar 2019

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen'. Together they form a unique fingerprint.

  • Cite this